174 related articles for article (PubMed ID: 9718357)
1. NTBC and alkaptonuria.
Anikster Y; Nyhan WL; Gahl WA
Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
[No Abstract] [Full Text] [Related]
2. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
[No Abstract] [Full Text] [Related]
3. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
Bird S; Miller NJ; Collins JE; Rice-Evans CA
J Inherit Metab Dis; 1995; 18(2):123-6. PubMed ID: 7564225
[No Abstract] [Full Text] [Related]
4. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E; Lindstedt S
J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
[TBL] [Abstract][Full Text] [Related]
5. NTBC as palliative treatment in chronic tyrosinaemia type I.
Ros J; Vilaseca MA; Lambruschini N; Mas A; Lindstedt S; Holme E
J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
[No Abstract] [Full Text] [Related]
6. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
Kassel R; Sprietsma L; Rudnick DA
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
[No Abstract] [Full Text] [Related]
7. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.
Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T
J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729
[TBL] [Abstract][Full Text] [Related]
8. The role of nitisinone in tyrosine pathway disorders.
Lock E; Ranganath LR; Timmis O
Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
[TBL] [Abstract][Full Text] [Related]
9. Promising new treatment for type I tyrosinemia.
Heubi JE
J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
[No Abstract] [Full Text] [Related]
10. Alkaptonuria.
Lorenzini S; Mannoni A; Selvi E
N Engl J Med; 2003 Apr; 348(14):1408; author reply 1408. PubMed ID: 12672874
[No Abstract] [Full Text] [Related]
11. New treatment for tyrosinaemia.
Lancet; 1992 Oct; 340(8823):822-3. PubMed ID: 1357248
[No Abstract] [Full Text] [Related]
12. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
[No Abstract] [Full Text] [Related]
13. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
[TBL] [Abstract][Full Text] [Related]
14. Alkaptonuria: treasure your exceptions.
Cox TM
J Inherit Metab Dis; 2011 Dec; 34(6):1113-4. PubMed ID: 21938512
[No Abstract] [Full Text] [Related]
15. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
[TBL] [Abstract][Full Text] [Related]
16. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
Mitchell GA
Hum Exp Toxicol; 1996 Feb; 15(2):179-81. PubMed ID: 8645506
[No Abstract] [Full Text] [Related]
18. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
[TBL] [Abstract][Full Text] [Related]
19. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Gissen P; Preece MA; Willshaw HA; McKiernan PJ
J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
[TBL] [Abstract][Full Text] [Related]
20. Suitability of nitisinone for alkaptonuria.
Häberle J
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):732-733. PubMed ID: 32822593
[No Abstract] [Full Text] [Related]
[Next] [New Search]